The US FDA has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Suzetrigine has a highly specific mechanism totally different from the way opioids dull pain. Opioids bind to receptors in the brain and spinal cord, providing system-wide pain relief and system ...

There is no escape from mental pain. It's necessary to learn techniques that soften the body's physiologic response to threats.

Unlike opioids, which bind to brain receptors to reduce pain but often lead to dependence ... dunk in that it’s a very different pathway and mechanism of action. So, I think that shows a lot ...

“But it is a slam dunk in that it’s a very different pathway and mechanism ... the opioid epidemic is mainly due to illicit fentanyl, not pharmaceutical medicines. Opioids reduce pain by ...

"Suzetrigine’s non-opioid mechanism eliminates risks of misuse, addiction and respiratory depression, making it a safer alternative for acute pain management." In addition to acute pain ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

Professor Dame Ijeoma Uchegbu discusses the nanoparticle delivery system behind the non-addictive pain medication Envelta and ...

The FDA has approved Vertex Pharmaceuticals’ Journavx, a new pain medication designed to reduce the risk of addiction and overdose associated with opioids. Intended for short-term pain after surgeries ...

How can a person manage pancreatic cancer back pain? Numerous treatments can help manage pancreatic cancer back pain. For most people who treat cancer pain with opioids, the drugs do not lead to ...

Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.

FDA approves suzetrigine, a non-opioid painkiller that blocks sodium channels, offering potent relief without addiction risks.